These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 24238512

  • 1. Famitinib in metastatic renal cell carcinoma: a single center study.
    Zhang W, Zhou AP, Qin Q, Chang CX, Jiang HY, Ma JH, Wang JW.
    Chin Med J (Engl); 2013 Nov; 126(22):4277-81. PubMed ID: 24238512
    [Abstract] [Full Text] [Related]

  • 2. Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
    Zhou A, Zhang W, Chang C, Chen X, Zhong D, Qin Q, Lou D, Jiang H, Wang J.
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1043-53. PubMed ID: 24043137
    [Abstract] [Full Text] [Related]

  • 3. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W, Yuan YC, Li MY, Kong W, Dong BJ, Chen YH, Zhang J, Xue W, Huang YR, Zhou LX, Huang JW.
    Zhonghua Zhong Liu Za Zhi; 2018 May 23; 40(5):384-389. PubMed ID: 29860767
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
    Sheng X, Chi Z, Cui C, Si L, Li S, Tang B, Mao L, Lian B, Wang X, Yan X, Guo J.
    Oncotarget; 2016 May 10; 7(19):27044-54. PubMed ID: 26894858
    [Abstract] [Full Text] [Related]

  • 5. Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial.
    Xu RH, Shen L, Wang KM, Wu G, Shi CM, Ding KF, Lin LZ, Wang JW, Xiong JP, Wu CP, Li J, Liu YP, Wang D, Ba Y, Feng JP, Bai YX, Bi JW, Ma LW, Lei J, Yang Q, Yu H.
    Chin J Cancer; 2017 Dec 22; 36(1):97. PubMed ID: 29273089
    [Abstract] [Full Text] [Related]

  • 6. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.
    Shi HZ, Tian J, Chen X, Wang D, Li CL.
    Clin Genitourin Cancer; 2017 Feb 22; 15(1):139-144. PubMed ID: 27338518
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
    Kim KH, Kim HY, Kim HR, Sun JM, Lim HY, Lee HJ, Lee S, Bae WK, Rha SY, Korean Cancer Study Group, Genitourinary & Gynecology Cancer Committee.
    Eur J Cancer; 2014 Mar 22; 50(4):746-52. PubMed ID: 24332573
    [Abstract] [Full Text] [Related]

  • 9. Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study.
    Chen Q, Tang L, Liu N, Han F, Guo L, Guo S, Wang J, Liu H, Ye Y, Zhang L, Liu L, Wang P, Li Y, He Q, Yang X, Tang Q, Li Y, Liang Y, Sun X, Xie C, Mo Y, Guo Y, Sun R, Mo H, Cao K, Guo X, Zeng M, Mai H, Ma J.
    Cancer Commun (Lond); 2018 Nov 01; 38(1):66. PubMed ID: 30382933
    [Abstract] [Full Text] [Related]

  • 10. Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety.
    Patel KB, Panchal HP, Karanwal AB, Parekh BB, Shah S, Prasad S.
    Indian J Cancer; 2016 Nov 01; 53(1):118-22. PubMed ID: 27146758
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
    Li XS, Wu X, Zhao PJ, Huang LH, Song Y, Gong K, Shen C, Yu W, Song G, Zhao Z, Zhang Z, Zhang Q, Wang G, He ZS, Zhou LQ, Jin J.
    Chin Med J (Engl); 2011 Sep 01; 124(18):2920-4. PubMed ID: 22040503
    [Abstract] [Full Text] [Related]

  • 12. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
    Rautiola J, Donskov F, Peltola K, Joensuu H, Bono P.
    BJU Int; 2016 Jan 01; 117(1):110-7. PubMed ID: 25252180
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
    Sternberg CN, Calabrò F, Bracarda S, Cartenì G, Lo Re G, Ruggeri EM, Basso U, Gasparini G, Ciuffreda L, Ferrari V, Bonetti A, Fea E, Gasparro D, Tassinari D, Labianca R, Masini C, Fly K, Zhang K, Hariharan S, Capaccetti B, Porta C.
    Oncology; 2015 Jan 01; 88(5):273-80. PubMed ID: 25592399
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors.
    Iacovelli R, Verri E, Cossu Rocca M, Aurilio G, Cullurà D, de Cobelli O, Nolè F.
    Anticancer Drugs; 2017 Feb 01; 28(2):206-212. PubMed ID: 27754995
    [Abstract] [Full Text] [Related]

  • 18. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
    Barrios CH, Hernandez-Barajas D, Brown MP, Lee SH, Fein L, Liu JH, Hariharan S, Martell BA, Yuan J, Bello A, Wang Z, Mundayat R, Rha SY.
    Cancer; 2012 Mar 01; 118(5):1252-9. PubMed ID: 21898376
    [Abstract] [Full Text] [Related]

  • 19. Central and Eastern European experience with sunitinib in metastatic renal cell carcinoma: a sub-analysis of the global expanded-access trial.
    Vrdoljak E, Géczi L, Mardiak J, Ciuleanu TE, Leyman S, Zhang K, Sajben P, Torday L.
    Pathol Oncol Res; 2015 Jul 01; 21(3):775-82. PubMed ID: 25557271
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.